Cancer Clinical Trial - Syndax

 

This study will evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of SNDX-5613 in participants with colorectal cancer (CRC) or other solid tumors who have failed at least 1 prior line of therapy.

Drug

SNDX-5613

Age Range

18 Years and older

Phase

Phase 1

Condition

metastatic CRC solid tumors